Portal de Periódicos da CAPES

Primary Site as a Prognostic Variable for Children with Pelvic Soft Tissue Sarcomas

1986; Lippincott Williams & Wilkins; Volume: 136; Issue: 4 Linguagem: Inglês

10.1016/s0022-5347(17)45109-3

1527-3792

Beverly Raney, Andrew R. Carey, Howard M. Snyder, John W. Duckett, Louise Schnaufer, Henrietta Kotlus Rosenberg, Soroosh Mahboubi, Jane Chatten, Philip Littman,

Surgical site infection prevention

No AccessJournal of Urology1 Oct 1986Primary Site as a Prognostic Variable for Children with Pelvic Soft Tissue Sarcomas Beverly Raney, Andrew Carey, Howard McC. Snyder, John W. Duckett, Louise Schnaufer, Henrietta K. Rosenberg, Soroosh Mahboubi, Jane Chatten, and Philip Littman Beverly RaneyBeverly Raney More articles by this author , Andrew CareyAndrew Carey More articles by this author , Howard McC. SnyderHoward McC. Snyder More articles by this author , John W. DuckettJohn W. Duckett More articles by this author , Louise SchnauferLouise Schnaufer More articles by this author , Henrietta K. RosenbergHenrietta K. Rosenberg More articles by this author , Soroosh MahboubiSoroosh Mahboubi More articles by this author , Jane ChattenJane Chatten More articles by this author , and Philip LittmanPhilip Littman Current address: Department of Radiation Oncology, Rhode Island Hospital, Providence, Rhode Island 02903. More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(17)45109-3AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail From 1974 to 1983 we treated 16 children between 1 and 16 years old for soft tissue sarcoma arising in the pelvis, bladder or prostate. An incisional biopsy was obtained in every patient. Each child then was treated with a combination chemotherapy program, incorporating vincristine, actinomycin D and cyclophosphamide with or without doxorubicin, cis-platinum and etoposide. Of the 16 patients 13 (81 per cent) also received radiation therapy. In 8 children with urinary obstruction or hematuria sarcomas arose in the bladder or bladder-prostate region, including 7 who had localized tumors and 1 who had lung metastases at diagnosis. The median tumor diameter in these patients was 5cm. Of these 8 patients 3 eventually required total cystectomy and prostatectomy to eradicate persistent local tumor, and 6 are alive and remain free of recurrent sarcoma for 1 to 9 years after initiation of therapy. The 8 other children had a pelvic mass at diagnosis, which arose adjacent to but outside of the bladder or prostate, and 2 had lung metastases at diagnosis. The median tumor diameter in these patients was 15cm. Only 3 of these 8 children are alive and remain free of sarcoma for 1 to 8 years after initiation of therapy. In only 1 of these children was complete tumor excision ever possible despite the use of local radiation therapy and aggressive chemotherapy. Sarcomas arising in the bladder-prostate region are found when relatively small, perhaps because they soon produce overt signs, and they appear to have a better prognosis than those arising in the retroperitoneum-pelvis outside the bladder. Better treatment strategies are needed for the latter group of tumors that often are locally uncontrollable. © 1986 by The American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited ByLerner S, Hayani A, O'Hollaren P, Winkel C, Ohori M, Harberg F, Roth D and Gonzales E (2018) The Role of Surgery in the Management of Pediatric Pelvic RhabdomyosarcomaJournal of Urology, VOL. 154, NO. 2, (540-545), Online publication date: 1-Aug-1995. Volume 136Issue 4October 1986Page: 874-878 Advertisement Copyright & Permissions© 1986 by The American Urological Association Education and Research, Inc.MetricsAuthor Information Beverly Raney More articles by this author Andrew Carey More articles by this author Howard McC. Snyder More articles by this author John W. Duckett More articles by this author Louise Schnaufer More articles by this author Henrietta K. Rosenberg More articles by this author Soroosh Mahboubi More articles by this author Jane Chatten More articles by this author Philip Littman Current address: Department of Radiation Oncology, Rhode Island Hospital, Providence, Rhode Island 02903. More articles by this author Expand All Advertisement Loading ...